Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 perioperative lenvatinib plus pembrolizumab with or without FLOT for gastric cancer
jRCT2031210174Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenvatinib, pembrolizumab, docetaxel, oxaliplatin, fluorouracil and 1 more in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 cohorts), sponsored by Merck & Co. Primary endpoint: Major pathological response rate by central review. Started Nov 2021; status: active, not recruiting.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031210174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210174.